Browse by goal
Peptides for Energy and Sleep: A Thin Evidence Base
Growth-hormone peptides like CJC-1295 and Ipamorelin can raise GH and IGF-1 in studies, but human evidence for energy and sleep benefits is thin, and they are research-use-only, not approved for human use.
Most discussed here: CJC-1295 · Ipamorelin
The compounds
Each one leads with how strong its human evidence is, and what that rating is based on.
- Prescription / GLP-1GHRH analogue (first 29 amino acids)
Sermorelin
Marketed to adults for sleep, body composition and aging. Approved use was growth hormone deficiency in children.
- Research peptidesMitochondria-targeted tetrapeptide
SS-31
Investigated for rare genetic mitochondrial disease. Sold online as a longevity and cellular-energy peptide.
- Research peptidesMitochondrial-derived peptide (16 amino acids)
MOTS-c
Sold for metabolic health, fat loss and longevity. Studied in humans as a biomarker of exercise response.
- Research peptidesNonapeptide
DSIP
Sold for sleep. Named in the 1970s after a proposed role in promoting delta-wave sleep.
- Research peptidesSynthetic GHRH (1-29) analogue
CJC-1295
Investigated as a long-acting growth hormone-releasing hormone analogue to raise GH and IGF-I. Reached Phase 2 and was discontinued; never approved for any indication.
- Research peptidesPentapeptide growth hormone secretagogue
Ipamorelin
Investigated for postoperative ileus, reaching Phase 2 before being discontinued for insufficient efficacy. Marketed to consumers for growth hormone release, an application never approved anywhere.
The reading
- Research peptides
CJC-1295: With DAC and Without DAC, Explained
Two molecules share one name and behave nothing alike. One has a published multi-day half-life, the other has no human PK study. Plus legal status and sport bans.
Read guide→ - Research peptides
DSIP: A Sleep Peptide Whose Research Mostly Stopped in the 1990s
DSIP has 519 papers behind it and 11 of them since 2015. The closest trial to how it is sold today ran in 1992. The name is doing most of the persuading.
Read guide→ - Research peptides
Ipamorelin: What the Clinical Record Shows
Ipamorelin is a growth hormone secretagogue that reached Phase 2 and stopped there. What the 1998 pharmacology found, and what the marketing leaves out.
Read guide→ - Research peptides
MOTS-c: The Human Studies Are About Exercise, Not Injections
Every MOTS-c protocol online gives you milligrams. The human research measures your own MOTS-c rising after exercise. That gap is the whole story of this compound.
Read guide→ - Prescription
Sermorelin: What the Trials Studied, and Who They Studied It In
Approved in 1997 for children with growth hormone deficiency, discontinued in 2008 - and the FDA says not for safety reasons. What the trials actually studied.
Read guide→ - Research peptides
SS-31 (Elamipretide): The Phase 3 Trial Missed Its Endpoints
SS-31 is a real drug in real trials for rare mitochondrial disease, not aging. Its largest controlled trial missed its primary endpoints. Vendors omit that.
Read guide→